Article Sidebar
Received:
Jul 20, 2022Accepted:
Sep 5, 2022Published:
Sep 27, 2022DOI:
10.4314/thrb.v23i4.2Keywords:
Article Details
Anésio M. de Sousa, Federal Institute of Tocantins – Araguatins
3. Prof. M.Sc. Federal Institute of Tocantins – Araguatins
Geraldo B. C. Junior, Federal University of Rio Grande do Norte
4. Prof. Dr. Federal University of Rio Grande do Norte
Luiz A. M. Filho, Federal University of Rio Grande do Norte
4. Prof. Dr. Federal University of Rio Grande do Norte
Main Article Content
Candida auris: a literature review
Dany G Kramer
Maria J. L da Silva
Anésio M. de Sousa
Geraldo B. C. Junior
Luiz A. M. Filho
Abstract
Background: Emerging pathogen Candida auris has been associated with nosocomial outbreaks demonstrating widespread antifungal resistance. This microorganism is associated with systemic infections with a high mortality rate, and studies that contribute to a better understanding of this agent are important.
Objectives: The present article aimed to carry out bibliographic research on Candida auris. Therefore, a literature search was carried out between January 2018 and January 2022, applying the following: C. auris; Candida auris and Infection, in Portuguese, English and Spanish. This review considers the available literature on C. auris and highlights key unknowns, which will provide guidance for future work in this field.
Results: The data collected in the present review allowed us to divide the theme into topics on Pathophysiology, Epidemiology/clinical and drug resistance mechanisms, so that the understanding of Candida auris can be better detailed and understood.
Conclusion: The predilection of C. auris by the most vulnerable and immunosuppressed patients or with comorbidities and with the potential to cause invasive and bloodstream infections with a propensity to cause outbreaks and concerns regarding resistance to antifungal agents, the fungus Candida auris, is of increasing clinical relevance. The increase in the number of detected cases and the occurrence of strains with multiple drug resistance prove to be worrisome, and applied research is essential to contribute to the knowledge of this strain and effective therapy.
Donate
AJOL is a Non Profit Organisation that cannot function without donations. AJOL and the millions of African and international researchers who rely on our free services are deeply grateful for your contribution. AJOL is annually audited and was also independently assessed in 2019 by E&Y.
Your donation is guaranteed to directly contribute to Africans sharing their research output with a global readership.
- Once off donations here:
- For annual AJOL Supporter contributions, please view our Supporters page.
Tell us what you think and showcase the impact of your research!
Please take 5 minutes to contribute to our survey so that we can better understand the contribution that African research makes to global and African development challenges. Share your feedback to help us make sure that AJOL's services support and amplify the voices of researchers like you.
AJOL Stakeholder Survey
We will share a selection of stories of impact on our website for millions of users to see.
Journal Identifiers
eISSN: 1821-9241
print ISSN: 1821-6404


